Previous 10 |
Acer Therapeutics (NASDAQ: ACER ) announces that the FDA has accepted for review Acer’s NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. More news on: Acer Therapeutics Inc., Healthcare sto...
Acer continues progress toward goal of commercializing EDSIVO™ NEWTON, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-r...
Seasoned veteran brings two decades of commercial experience to Acer Acer continues to execute on activities towards its goal of commercializing EDSIVO™ NEWTON, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on...
Acer Therapeutics (NASDAQ: ACER ) has filed a New Drug Application (NDA) with the FDA seeking approval for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by defects in a gene that encodes collagen. The company has requ...
Requests Priority Review NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need...
ACER data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. The Company went public on September 19, 2017 following a merger and plan of arrangement between Opexa Therapeutics and privately h...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023